Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PDE8B | O95263 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842338 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL2842945 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL585006 | 0.89 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL583956 | 0.89 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL25366293 | 0.87 | FKBP1A (0.31) | FKBP1A | |
| SCHEMBL25366297 | 0.87 | FKBP1A (0.31) | FKBP1A | |
| SCHEMBL7123624 | 0.86 | ALDH1A1 (0.37) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL31080875 | 0.86 | ALDH1A1 (0.37) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL17930991 | 0.85 | PARP1 (0.35) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL5497620 | 0.84 | CYP19A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | ALDH1A1 2770/4885TSHR 1098/4885MEN1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.